Condition (MeSH)
Zollinger-Ellison Syndrome
ClinicalTrials.gov lists 16 trials for Zollinger-Ellison Syndrome or a narrower condition beneath it. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
16 of the 16 trials are tagged with Zollinger-Ellison Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Zollinger-Ellison Syndrome trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2017 | 1 |
| 2014 | 1 |
| 2011 | 2 |
| 2010 | 1 |
| 2009 | 1 |
| 2007 | 1 |
| 2005 | 1 |
| 2003 | 2 |
| 1991 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 16 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Zollinger-Ellison Syndrome trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 2 |
| Phase 4 | 1 |
| Observational | 4 |
How many Zollinger-Ellison Syndrome trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 14 |
| Terminated | 1 |
| Withdrawn | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Zollinger-Ellison Syndrome trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 6 |
| AstraZeneca | 3 |
| National Cancer Institute (NCI) | 2 |
| Takeda | 1 |
| Trio Medicines Ltd. | 1 |
Which drugs are being tested for Zollinger-Ellison Syndrome? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| "Capecitabine" | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SOC: Temozolomide | 2 |
| combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin | 1 |
| Clopidogrel and Esomeprazole | 1 |
| Interferon | 1 |
| Nexium Pill | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Zollinger-Ellison Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Mucosal relapse | 12 | 1 |
| Death NOS | 11 | 1 |
| Death | 10 | 2 |
| Cancer | 5 | 1 |
| Death (metastatic gastrinoma) | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Zollinger-Ellison Syndrome? (23)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. | Medicine | 2013 | Yes |
| Zollinger-Ellison syndrome: presentation, response to therapy, and outcome. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2011 | Yes |
| Costs and risks in the management of patients with gastric acid hypersecretion. | Journal of clinical gastroenterology | 2010 | Yes |
| Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. | BMC gastroenterology | 2008 | Yes |
| Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia. | Alimentary pharmacology & therapeutics | 2007 | Yes |
Showing 5 of 23 publications.
Prevalence (18)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Zollinger-Ellison syndrome | Annual incidence | 1-9 / 1 000 000 | Worldwide | Not stated | Exact |
| Zollinger-Ellison syndrome | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Zollinger-Ellison syndrome | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Zollinger-Ellison syndrome | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Zollinger-Ellison syndrome | Annual incidence | 1-9 / 1 000 000 | Switzerland | Not stated | Exact |
Showing 5 of 18 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Zollinger-Ellison syndrome | 913 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Zollinger-Ellison syndrome | 913 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.